Results 111 to 120 of about 49,774 (199)

Real-world validation of a reduced-dose continuous infusion cefepime regimen: pharmacodynamic target attainment, efficacy and neurotoxicity. [PDF]

J Antimicrob Chemother
Korvin K, Goutelle S, Laffont-Lozes P, Villa F, Martin A, Chiaruzzi M, Loubet P, Sotto A, Larcher R.   +8 more
europepmc   +1 more source

Synergistic activity of cefepime/enmetazobactam with meropenem, piperacillin, piperacillin/tazobactam, cefiderocol and fosfomycin against Klebsiella pneumoniae carrying blaKPC allelic variants. [PDF]

J Antimicrob Chemother
Crema A, Shafique A, Bianco G, Gaibani P.   +3 more
europepmc   +1 more source

Cefepime Combined with Late-Generation β-Lactamase Inhibitors: Mechanisms of Action, In Vitro Activity, PK/PD Characteristics, Clinical Evidence and Resistance Mechanisms. [PDF]

Antibiotics (Basel)
Comini S, Boattini M, Gaibani P, Bianco G.   +3 more
europepmc   +1 more source

Identification and assessment of paediatric cefepime-induced neurotoxicity in a retrospective cohort of paediatric intensive care patients. [PDF]

J Antimicrob Chemother
Pavia K, Day ME, Hambrick HR, Sibilia A, Fenchel M, Paice K, Kaplan J, Tang Girdwood S.   +7 more
europepmc   +1 more source

Venous thromboembolism related to cytomegalovirus infection: A case report and literature review [PDF]

, 2017
Farrell, John J, Jacob, Kavitha S, Kelkar, Amar H, Yousif, Eman B   +3 more
core   +2 more sources

Questions regarding mortality and infection source in deep-seated infections. [PDF]

Antimicrob Agents Chemother
Nishimura S.
europepmc   +1 more source

Safety concerns associated with high-dose continuous infusion of cefepime among critically ill patients with mild renal impairment to augmented renal clearance at a level 1 trauma center: CEFTOX study. [PDF]

Antimicrob Agents Chemother
Lamamri M, Rutman C, Codorniu A, Holleville M, Sigaut S, Weiss E, Jeantrelle C.   +6 more
europepmc   +1 more source

Elevated hippocampal and cortical cefepime concentrations correlate with seizures in an acute kidney injury rat model. [PDF]

Antimicrob Agents Chemother
Pais GM, Lesnicki E, Marianski S, Valdez K, Gibson Z, Christopher J, Lepard K, Gilchrist A, Mizuno T, Scheetz MH.   +9 more
europepmc   +1 more source

Individualizing beta-lactam dosing in real-world patients: lessons from a pharmacist-led programme implementation and evaluation. [PDF]

JAC Antimicrob Resist
Pan S, Weslander E, Fierek S, Ball M, Crutchfield CA, Galvin S, Rhodes NJ.   +6 more
europepmc   +1 more source

Strategies for Safer Cefepime Use to Prevent Neurotoxicity Using the Electronic Health Record. [PDF]

Crit Care Explor
Zafar SF, Park H, Letourneau AR, Rock AE, Westover MB, Mukerji SS.   +5 more
europepmc   +1 more source